+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

CLINICIAN-SCIENTIST EMERGING LEADER AWARD

Foundation Fighting Blindness Canada

Fighting Blindness Canada’s Clinician-Scientist Emerging Leader (CSEL) award supports ophthalmologists and optometrists in Canada who integrate research into their careers. This competition will fund projects with the potential to significantly impact Canadians living with a retinal eye disease including, but not limited to inherited retinal diseases, age related macular degeneration, diabetic retinopathy and glaucoma.

Applicants can apply for funding at two levels, up to $20,000 or up to $40,000 over two years, dependent on the amount of protected research time they have.

Registration Deadline: May 7, 2026, 5 p.m. EST –
Full Application Deadline: June 11, 2026, 5 p.m. EST

AI Based Application Success Predictor

1. Strong relevance to inherited retinal disease and vision loss

The most competitive applications directly address:

retinitis pigmentosa,
Stargardt disease,
Usher syndrome,
Leber congenital amaurosis,
optic nerve degeneration,
retinal degeneration,
inherited retinal diseases (IRDs),
dry age-related macular degeneration,
retinal neurodegeneration.

FBC explicitly funds research aimed at “treatments and cures for blinding eye diseases.”

2. Clear translational and therapeutic impact

One of the strongest predictors of success is:

realistic therapeutic potential,
vision preservation or restoration,
clinically actionable discoveries,
translational feasibility,
improvement in patient outcomes.

FBC’s grant competitions specifically prioritize research accelerating “development and availability of treatments and cures.”

3. Strong alignment with retinal research priorities

Competitive applications commonly align with:

gene therapy,
retinal regeneration,
precision ophthalmology,
neuroprotection,
retinal imaging biomarkers,
inherited retinal disease genomics,
translational ophthalmology.

The organization has historically funded stem-cell therapies, neuroprotective therapies, pharmaceuticals, and gene therapies.

4. Strong methodological rigor

Successful proposals generally demonstrate:

robust retinal-disease models,
validated imaging or molecular assays,
reproducibility,
strong statistical planning,
feasible recruitment and timelines,
realistic milestones.

Weak methodological design is a common reviewer concern across retinal funding systems.

5. Strong preliminary or proof-of-concept data

Applications with:

pilot retinal imaging findings,
proof-of-concept rescue studies,
preliminary gene-editing or gene-therapy data,
feasibility studies,
translational biomarker evidence

typically receive stronger reviewer confidence.

6. Innovation and advanced therapeutic technologies

Highly competitive projects often involve:

gene editing,
AAV/nonviral delivery systems,
stem-cell retinal regeneration,
RNA therapeutics,
optogenetics,
AI-assisted retinal analysis,
precision medicine,
neuroprotective strategies.

FBC-supported research has contributed to major advances in gene therapy and vision-restoration science.

7. Strong interdisciplinary collaboration

High-scoring projects frequently involve:

ophthalmologists,
retinal specialists,
neuroscientists,
geneticists,
bioinformaticians,
imaging experts,
translational scientists,
computational biologists.

Collaborative retinal research ecosystems substantially strengthen applications.

8. Strong support for early-career investigators

FBC specifically runs Early Career Research Grant competitions supporting:

discovery research,
translational retinal science,
clinical research,
epidemiologic ophthalmology.

Strong mentorship and institutional support significantly improve competitiveness for junior investigators.

9. Feasible clinical and implementation pathway

Reviewers strongly favor:

realistic translational timelines,
scalable therapeutic development,
patient-access feasibility,
registry or clinical-network integration,
measurable translational milestones.

FBC maintains patient-registry and clinical-research infrastructure supporting translational work.

10. Potential for future major funding and clinical advancement

Competitive proposals are often those likely to:

generate CIHR/NIH/NEI funding,
advance to clinical trials,
create scalable retinal therapeutics,
produce high-impact publications,
strengthen Canadian retinal research networks.

FBC has invested more than $42 million into vision research leading to hundreds of scientific discoveries.

Common Reasons for Rejection

Frequent reviewer concerns include:

weak inherited-retinal-disease relevance,
insufficient translational significance,
inadequate preliminary evidence,
unrealistic therapeutic scope,
weak mechanistic rationale,
poor statistical planning,
limited feasibility,
insufficient innovation.

Specialties

Ophthalmology

Eligibility Requirements

• Candidates must hold or be enrolled in a clinical doctoral degree (MD, OD etc.).

• Preferred candidates are in the final year of their clinical doctoral degree or enrolled in an ophthalmology or optometry residency or fellowship program in Canada.

• Candidates must be Canadian citizens or permanent residents of Canada.

• Candidates are ineligible if: o They are holding or have held a CSEL award. o It has been more than 8 years* since being awarded their clinical doctoral degree at the start of the award (e.g. October 1, 2026)

• Applicants must identify one or two mentors who are active clinician-scientists with faculty appointments, to guide their research proposal.

Sponsor Details

Sponsor Institute/Organizations: Foundation Fighting Blindness Canada

Sponsor Type: Corporate/Non-Profit

Address: 890 Yonge St 12th floor Toronto, ON, M4W 3P4

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity